450 F.Supp.3d 278
E.D.N.Y2020Background
- Nutra Pharma (inc. 2000) and CEO/operator Erik Deitsch marketed cobra-venom pain relievers from ~2013–2018 while the company was unprofitable and had not produced the products it touted.
- Deitsch authorized and controlled press releases and SEC filings that touted third‑party endorsements (Wall Street Buy, SeeThruEquity) and distribution deals (e.g., Nature’s Clinic in Canada, prospective deals in India and China).
- Nutra Pharma paid promoters (Wall Street Buy, SeeThruEquity) but some press materials omitted that compensation or characterized the research as "not paid for" and "unbiased."
- Deitsch made small, unusual trades in Nutra Pharma stock (flagged by brokers as manipulative); SEC alleges market‑manipulative intent.
- Sean McManus, a former FINRA‑barred individual, solicited investors on Nutra Pharma’s behalf; SEC alleges he acted as an unregistered broker.
- Procedural posture: SEC filed an Amended Complaint alleging multiple securities violations; defendants moved to dismiss. Court granted motions in part, denied them in part, dismissed allegations tied to Wall Street Buy press releases (because disclosures appeared in linked videos), and directed the SEC to file a more definite Second Amended Complaint within 30 days.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Material misstatements/omissions in press releases and Form 10‑Q (Securities Act §17(a), Exchange Act §10(b)/Rule 10b‑5) | Statements and half‑truths (promotional quotes, distribution claims, cobra‑farm/production claims) were materially misleading and made with scienter. | Releases were literally true or forward‑looking with cautionary language; promoters had the duty to disclose their compensation, not the issuer. | Court denied dismissal as to SeeThruEquity and distribution releases (sufficiently pleaded material misstatements and scienter); dismissed Wall Street Buy release allegations because linked videos disclosed compensation. |
| Liability for promoting third‑party reports (duty to disclose promoter compensation) | Nutra Pharma had duty to ensure its own press release statements were accurate and complete once it republished/endorsed third‑party praise. | Promoters bore the disclosure burden under Section 17(b); issuer shouldn’t be liable if promoter disclosed separately. | Court: issuer cannot republish or emphasize third‑party endorsements without accurate/complete disclosures; denied dismissal for SeeThruEquity; Wall Street Buy disclosures in linked videos were deemed sufficient at pleading stage. |
| Market manipulation / manipulative trading (Exchange Act §10(b) and §9(a)(2)) | Deitsch’s small, uneconomical buys and above‑ask purchases were manipulative and plead scienter. | Trades were intended to deter short sellers (protect the stock), not to manipulate. | Court held allegations collectively gave rise to a strong inference of scienter; denied dismissal. |
| False certification of periodic reports (Exchange Act §13(a), Rule 13a‑14) | Deitsch certified SEC filings that contained the same misleading statements as the press releases. | Certifications were not false because statements were forward‑looking or literally true. | Court denied dismissal; claims tied to previously sustained misstatements survive. |
| McManus as an unregistered broker (Exchange Act §15(a)) | McManus solicited investors, attended promotional events, and was paid for investor‑relations work—acting as a broker without registration. | SEC failed to allege McManus effected transactions or met broker factors. | Court found sufficient allegations of solicitation, active investor‑finding, and compensation; denied dismissal. |
| Aiding and abetting claims | Aiding and abetting pleadings track primary violations; survive if primaries survive. | Should be dismissed absent primary violations. | Court denied dismissal because primary claims were adequately pleaded. |
Key Cases Cited
- Ashcroft v. Iqbal, 556 U.S. 662 (2009) (pleading must state a plausible claim)
- Bell Atl. Corp. v. Twombly, 550 U.S. 544 (2007) (plausibility standard for complaints)
- Tellabs, Inc. v. Makor Issues & Rights, Ltd., 551 U.S. 308 (2007) (collective‑inference standard for scienter)
- Ernst & Ernst v. Hochfelder, 425 U.S. 185 (1976) (scienter encompasses intent to deceive, manipulate, or defraud)
- Halperin v. eBanker USA.com, Inc., 295 F.3d 352 (2d Cir. 2002) (materiality assessed by whether statements affect the total mix of information)
- Caiola v. Citibank, N.A., 295 F.3d 312 (2d Cir. 2002) (duty to be accurate and complete when choosing to speak)
- SEC v. Syron, 934 F. Supp. 2d 609 (S.D.N.Y. 2013) (half‑truths can support securities fraud claims)
- SEC v. Fiore, 416 F. Supp. 3d 306 (S.D.N.Y. 2019) (discussion of materiality and scienter in enforcement actions)